Vicus Therapeutics Announces Initiation of Phase 2 Trial to Evaluate VT-122 in Patients with Liver Cancer Receiving Nexavar
12/27/2010 9:28:20 AM
More...
|
Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
5/1/2008 7:49:38 AM
More...
|
Vicus Therapeutics' Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels
10/5/2007 9:42:02 AM
More...
|
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8/16/2007 9:44:18 AM
More...
|
Vicus Therapeutics to Present Results from Investigator-led Cancer Cachexia Studies at the 12th Congress of the Japanese Society for Palliative Medicine
6/19/2007 10:51:28 AM
More...
|
Vicus Therapeutics Announces Participation at 14th International Molecular Medicine Tri-Conference
3/1/2007 9:55:29 AM
More...
|
John Maki, CEO Of Vicus Therapeutics, Elected To Biotechnology Council Of New Jersey Board Of Trustees
2/6/2007 1:04:55 PM
More...
|